Be sure to check our sister interview main ratings news website

Open Orphan name change to hVIVO effective 26th October 2022

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that further to its announcement on 8 September 2022, the Company’s change of name to hVIVO plc (LON:HVO) has now been completed and is expected to take effect on AIM and Euronext Growth from 8.00 am tomorrow.

The Company’s ticker will be HVO and the website address (including the investor relations content and the information required by AIM Rule 26 and Euronext Growth Rule 3.4) will be available at www.hvivo.com.

The Company’s ISIN (GB00B9275X97) and SEDOL (B9275X9) will remain the same.

Shareholders will be unaffected by the change of name and existing share certificates should be retained and will remain valid. Any new share certificates issued after the name change takes effect will bear the name hVIVO plc.

Read in Full
Click to view all articles for the EPIC: ,
Or click to view the full company profile:
Facebook
X
LinkedIn
Open Orphan Plc

More articles like this

hVIVO plc

Blood biomarkers for viral infection diagnosis and management

18th December 2024

Host response biomarkers to viral infections have significant potential in clinical applications, such as guiding diagnostic decisions, reducing unnecessary antibiotic use, and triggering infection control protocols or antiviral treatments. Research on these biomarkers has largely focused

hVIVO plc

Impact of patient perception on vaccine and drug efficacy

13th December 2024

Human viral challenge studies have become essential in evaluating the effectiveness of vaccines, treatments, and prophylactics, providing quicker results compared to larger Phase 2a/b field trials. hVIVO has developed various challenge agents for human use, including

hVIVO plc

Versatile MDCK cells in research and biotechnology

29th November 2024

MDCK (Madin-Darby Canine Kidney) cells are an essential tool in biological and medical research, especially in virology, cell biology, and studies involving membrane transport. Originally derived in 1958 from the kidney of a healthy adult female

hVIVO plc

Exploring the human viral challenge model for influenza research

25th November 2024

This study evaluates the human viral challenge model using the A/Perth/16/2009 H3N2 influenza virus, involving 216 volunteers across five clinical studies. Administered intranasally under controlled conditions, the research aimed to improve the understanding of influenza infection

hVIVO plc

Advancing influenza research with new challenge agents

18th November 2024

Controlled Human Infection Studies (CHIS) have proven to be essential in exploring human responses to respiratory infections and testing the effectiveness of vaccines and treatments. These studies hinge on selecting an appropriate challenge virus, making a

hVIVO plc

hVIVO’s patient enrolment & retention at Canary Wharf

15th November 2024

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

hVIVO plc

Inside hVIVO’s cutting-edge QA facility at Canary Wharf

8th November 2024

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

hVIVO plc

Virus portfolio for RSV research and development

5th November 2024

Respiratory Syncytial Virus (RSV), discovered in 1956, is a common and contagious RNA virus responsible for a range of respiratory illnesses worldwide. Initially identified by Dr. Robert Chanock and colleagues in chimpanzees, RSV belongs to the

hVIVO plc

Clinical trial eligibility: Pre-screening and Screening

29th October 2024

In clinical trials, ensuring patient safety is paramount, and researchers must identify suitable participants who meet specific requirements. To this end, there are distinct processes involved, known as pre-screening and screening, which help determine whether a

hVIVO plc

Connecting Airway Epithelial Cell Models with Human Challenge Studies

24th October 2024

Airway epithelial cells cultured in Air–Liquid Interface (ALI) conditions provide an environment that closely resembles the human airway system. This method facilitates improved oxygen availability and supports cellular differentiation, replicating the physiological conditions of the human

hVIVO plc

Esmée shares her FluCamp clinical trial volunteer experience

21st October 2024

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

hVIVO plc

Overcoming challenges in high-growth regulated industries

18th October 2024

The Navigating Risk podcast recently explored the challenges faced by high-growth businesses operating in highly regulated industries, particularly life sciences. Helen Yates, the Editor of Global Thought Leadership, engaged in a conversation with Mo Khan, the

© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.